Join the club for FREE to access the whole archive and other member benefits.

Rubedo Life Sciences

Extending Health Span and Reverting Age-Related Diseases.

Rubedo Life Sciences is an anti-aging company based in the Silicon Valley, California. Rubedo mission is to extend health-span by targeting cell in the body in an accurate and safe way. We aim to remove from the body "bad cells"​ that drive agin (such as the pro-inflammatory senescent cells), and to improve functions of "good cells (such as stem cells). Rubedo is developing treatments for aged-related diseases such as Alzheimer’s, Cancer, Diabetes, or Arthritis. The company is founded and driven by leaders in aging, regenerative medicine, senescence, combinatorial and medicinal chemistry from top academics (such as Stanford, Berkley and Cambridge UK) and top life sciences companies (such as Affymax, Xenoport, Verily).

Visit website:


Details last updated 09-Sep-2020

People at Rubedo Life Sciences

Marco Quarta

Co-Founder CEO at Rubedo Life Sciences

Rubedo Life Sciences News

Reason reports back from Rejuvenation Startup Summit 2024

Fight Aging! - 13-May-2024

A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials


Rubedo secures $40 million to advance its age-targeting treatments into clinical trials

Longevity Technology - 22-Apr-2024

Potentially leading to breakthroughs in managing chronic diseases


Reason reports back from Age-Related Disease Therapeutics Summit 2023

Fight Aging! - 16-Jun-2023

Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years


Rubedo's lead compound targets inflammatory skin disease with selective senolytic approach

Business Wire - 20-Mar-2023

Rubedo is planning first-in-human studies in multiple skin indications driven by chronic inflammation

Read more... summarises the proceedings of the Buck Institute's Longevity Summit (LEAF) - 20-Jan-2023

Another reminder of the amount of research, with multiple approaches, about to go into clinical trials


Super summary of 3rd Annual Longevity Therapeutics Summit (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year


Rubedo to first work on lung diseases

Longevity Technology - 20-Jan-2021

Their work will be critical amidst the COVID-19 pandemic - to move into clinical trials soon


LMC provides background and success outlook on 14 leading senolytic companies

Longevity Marketcap - 15-Dec-2020

Comprehensive review of companies' clinical and financial state of play

Topics mentioned on this page:
Senescent Cells, Stem Cells